Sucampo Pharmaceuticals to Present at Investment Conferences BIO CEO & Investor Conference 2013 Business Wire BETHESDA, Md. -- February 6, 2013 Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it will webcast its corporate presentation at two upcoming investment conferences in New York City: *Mr. Cary J. Claiborne, CFO of Sucampo, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12 at 1:00 pm Eastern. *Mr. Claiborne will also host a fireside chat at the Leerink Swann Global Healthcare Conference 2013 on Thursday, February 14 at 1:30 pm Eastern. The presentations will be webcast live and may be accessed from the Event Calendar page of Sucampo’s website at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar. Presentation slides will be available via the webcast links. A replay of both webcasts will also be available on the Company’s website for several days after the live events. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast. About Sucampo Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com. Sucampo Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which the Company incorporates by reference. Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor, 1-240-223-3718 firstname.lastname@example.org
Sucampo Pharmaceuticals to Present at Investment Conferences
Press spacebar to pause and continue. Press esc to stop.